19 Jul 2021

Bristol-Myers Squibb International Corporation
Email: Clinical.Trials@bms.com
Chaussée de la Hulpe 185
Brussels, Belgium
1170

EudraCT Number: 2015-002505-11
Sponsor Protocol Number: CA009-002

A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Solid Tumors

Trial 2015-002505-11 has a new planned date for results disclosure to EudraCT and CT.gov of 15Dec2022 (initially was 15Dec2020)

- Justification for this delay is per the allowance of the Certificate of Delay submitted to ClinicalTrials.gov for the category of *Certify Initial Approval*, detailed below:
    - Certify initial approval: The study was completed before the drug or device is initially approved, licensed, or cleared by the Food and Drug Administration (FDA). This will be a delay for up to 2 years or 30 days following approval, whichever is first.
    - Considering the delay of results disclosure for CT.gov, we wanted to align the disclosure timelines for EudraCT and therefore equally delay the EudraCT results submission.